Bibliografía
1. Otten HM, Mathijssen J, ten Cate H, Soesan M, Inghels M, Richel DJ, Prins MH. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med. 2004 Jan 26;164(2):190-4. [PubMed]
2. . Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020 Feb 10;38(5):496-520. [PubMed]
3. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 May 15;111(10):4902-7. [PubMed]
4. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010 Dec 9;116(24):5377-82. [PubMed]
5. Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012 Jun;7(3):291-2. [PubMed]
6. Pelzer U, Sinn M, Stieler J, Riess H. Primäre medikamentöse Thromboembolieprophylaxe bei ambulanten Patienten mit fortgeschrittenem Pankreaskarzinom unter Chemotherapie? [Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?]. Dtsch Med Wochenschr. 2013 Oct;138(41):2084-8. German. [PubMed]
7. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al.; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015 Feb 20;33(6):654-6. [PubMed]
8. van Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten H-M, Mahé I, et al. Comparison of risk prediction scores for cancer-associated venous thromboembolism: A prospective cohort study. Haematologica. 2017 Sep;102(9):1494-501. [PubMed]
9. Ugarte Fornell G, Otero Candelera R, Ferrer Galván M, Morillo Guerrero R, Elias Hernández T, Jara Palomares L. Predictive Khorana's model in patients with venous thromboembolic disease and cancer. Med Clin (Barc). 2013 Dec 7;141(11):479-81. [PubMed]
10. Srikanthan A, Tran B, Beausoleil M, Jewett MA, Hamilton RJ, Sturgeon JF, et al. Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. J Clin Oncol. 2015 Feb 20;33(6):582-7. [PubMed]
11. Ramos JD, Casey MF, Bamias A, De Giorgi U, Bellmunt J, Harshman LC, et al. The Khorana score in predicting venous thromboembolism for patients with metastatic urothelial carcinoma and variant histology treated with chemotherapy. Clin Appl Thromb Hemost. 2016 Jan 1:1076029616668405. [PubMed]
12. Muñoz Martín AJ, García Alfonso P, Rupérez Blanco AB, Pérez Ramírez S, Blanco Codesido M, Martín Jiménez M. Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model. Clin Transl Oncol. 2014 Oct;16(10):927-30. [PubMed]
13. Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost. 2016 Sep;14(9):1773-8. [PubMed]
14. Pépin M, Kleinjan A, Hajage D, Büller HR, Di Nisio M, Kamphuisen PW, et al. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer. J Thromb Haemost. 2016 Feb;14(2):306-15. [PubMed]
15. Cella CA, Di Minno G, Carlomagno C, Arcopinto M, Cerbone AM, Matano E, et al. Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. Oncologist. 2017 May;22(5):601-8. [PubMed]
16. Godinho J, Casa-Nova M, Moreira-Pinto J, Simões P, Paralta Branco F, Leal-Costa L, et al. ONKOTEV Score as a Predictive Tool for Thromboembolic Events in Pancreatic Cancer-A Retrospective Analysis. Oncologist. 2020 Feb;25(2):e284-e290. [Enlace]
17. Cella CA, Knoedler M, Hall M, Arcopinto M, Bagnardi V, Gervaso L, et al. Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer. JAMA Netw Open. 2023 Feb 1;6(2):e230010. [Enlace]
18. Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S, et al. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. Oncologist. 2017 Oct;22(10):1222-31. [PubMed]
19. Walker AJ, West J, Card TR, Crooks C, Kirwan CC, Grainge MJ. When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data. Blood. 2016 Feb 18;127(7):849-57. [PubMed]
20. RupaMatysek J, Lembicz M, Rogowska EK, Gil L, Komarnicki M, BaturaGabryel H. Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients. Med Oncol. 2018 Apr 3;35(5):63. [PubMed]
21. Spyropoulos AC, Eldredge JB, Anand LN, Zhang M, Qiu M, Nourabadi S, et al. External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model. Oncologist. 2020 Jul;25(7):e1083-e1090. [Enlace]
22. Pabinger I, Ay C, Dunkler D, Thaler J, Reitter EM, Marosi C, et al. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients: results from the Vienna Cancer And Thrombosis Study (CATS). J Thromb Haemost. 2015 Jan;13(1):17-22. [PubMed]
23. Gran OV, Smith EN, Brækkan SK, Jensvoll H, Solomon T, Hindberg K, et al. Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism. Haematologica. 2016 Sep;101(9):1046-53. [PubMed]
24. Roselli M, Ferroni P, Rolfo C, Peeters M, Palmirotta R, Formica V, et al. TNF-α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy. Ann Oncol. 2013 Oct;24(10):2571-5. [PubMed]
25. Brand JS, Hedayati E, Humphreys K, Ludvigsson JF, Johansson AL, Bergh J, et al. Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients. Clin Cancer Res. 2016 Nov 1;22(21):5249-5255. [PubMed]
26. Muñoz Martín AJ, Ortega I, Font C, Pachón V, Castellón V, Martínez-Marín V, et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer. 2018 Apr;118(8):1056-61.
27. Muñoz A, Ay C, Gritz E, López S, Font C, Pachón V, et al. A Clinical-genetic Risk Score to Predict Cancer-associated Venous Thromboembolism: A Development and Validation Study in Two Independent Prospective Cohorts. Oral Communication (OC) 15.5. ISTH 2019: The XXVII Congress of the International Society on Thrombosis and Haemostasis. Melbourne, Australia: ISTH; July 6-10, 2019. [Enlace]
28. Muñoz A, Ay C, Grilz E, López S, Font C, Pachón V, et al. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts. J Clin Oncol. 2023 Jun 1;41(16):2911-25. [PubMed]
29. Bastos Oreiro M, Ortiz J, Pradillo V, Martínez Laperche C, Salas E, Buño I, Díez JL et al. A Validation, with New Clinical Applicability, of a Clinical-genetic Risk Model that Predicts Thrombosis with High Sensitivity in Patients with Lymphoma. OC 41.3. ISTH 2019: The XXVII Congress of the International Society on Thrombosis and Haemostasis. Melbourne, Australia: ISTH; July 6-10, 2019. [Enlace]
30. Bastos-Oreiro M, Ortiz J, Pradillo V, Salas E, Marínez-Laperche C, Muñoz A, et al. Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma. Cancer Med. 2021 Nov;10(21):7585-92. [PubMed]
31. Pabinger I, van Es N, Heinze G, Posch F, Riedl J, Reitter EM, et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol. 2018 Jul;5(7):e289-e298. Erratum in: Lancet Haematol. 2018 Jun 15. [PubMed]
32. Li A, La J, May SB, Guffey D, da Costa WL Jr, Amos CI, et al. Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems. J Clin Oncol. 2023 Jun 1;41(16):2926-38. [PubMed]
33. Antic D, Milic N, Todorovic M, Bila J, Andjelic B, Djurasinovic V, et al. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. Am J Hematol. 2016 Oct;91(10):1014-9.
34. Norris LA, Ward MP, O'Toole SA, Marchocki Z, Ibrahim N, Khashan AS, et al. A risk score for prediction of venous thromboembolism in gynecologic cancer: The Thrombogyn score. Res Pract Thromb Haemost. 2020 May 28;4(5):848-59. [PubMed]
35. Bezan A, Posch F, Ploner F, Bauernhofer T, Pichler M, Szkandera J, et al. Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. PLoS One. 2017 Apr 21;12(4):e0176283. [PubMed]
36. Antic D, Biljana M, Milic N, Cheson BD, Narkhede M, Panovska I, et al. Internal and external validation of THROLY (THROmbosis LYmphoma) score. Oral Communication 10. 9th International Conference on Thrombosis & Hemostasis Issues in Cancer (ICTHIC) 2018. Bergamo (Italy), 13-15 April 2018. Disponible en: [Enlace]
37. Antic D, Jelicic J, Vukovic V, Nikolovski S, Mihaljevic B. Venous thromboembolic events in lymphoma patients: Actual relationships between epidemiology, mechanisms, clinical profile and treatment. Blood Rev. 2018 Mar;32(2):144-58. [PubMed]
38. Alexander M, Ball D, Solomon B, Mac Manus M, Manser R, Riedel B, et al. Dynamic Thromboembolic Risk Modelling to Target Appropriate Preventative Strategies for Patients with Non-Small Cell Lung Cancer. Cancers (Basel). 2019 Jan 8;11(1):50. [PubMed]
39. Alexander M, Harris S, Underhill C, Torres J, Sharma S, Lee N, et al. Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial. JAMA Oncol. 2023 Nov 1;9(11):1536-45. [PubMed]
40. Posch F, Riedl J, Reitter EM, Crowther MJ, Grilz E, Quehenberger P, et al. Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: a prospective study. J Thromb Haemost. 2020 Jun;18(6):1348-56. [PubMed]
41. Van es N. Dynamic prediction modeling for cancer-associated venous thromboembolism. J Thromb Haemost. 2020 Jun;18(6):1276-7. [PubMed]
42. Di Nisio M, van Es N, Rotunno L, Anzoletti N, Falcone L, De Tursi M, et al. Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. J Thromb Thrombolysis. 2019 Jul;48(1):125-33. [PubMed]
43. Zugazagoitia J, Biosca M, Oliveira J, Olmedo ME, Dómine M, Nadal E, et al. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer. Eur Respir J. 2018 May 3;51(5):1702431. [PubMed]
44. Qin L, Liang Z, Xie J, Li X. Estimating Venous Thromboembolism Risk in Metastatic Colorectal Cancer Inpatients: Validation of Existing Risk Scores and Development of New Risk Scores. Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231196859. [PubMed]
45. Carrier M, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med. 2014 Jan;127(1):82-6.e1. [PubMed]
46. Patell R, Rybicki L, McCrae KR, Khorana AA. Predicting risk of venous thromboembolism in hospitalized cancer patients: Utility of a risk assessment tool. Am J Hematol. 2017 Jun;92(6):501-7. [PubMed]
47. Dana E. Angelini, Todd Greene M, Wietzke JN, Flanders SA, Sood SL. A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score. Blood (2016) 128 (22): 1181. [Enlace]
48. Louzada ML, Carrier M, Lazo-Langner A, Dao V, Kovacs MJ, Ramsay TO, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation. 2012 Jul 24;126(4):448-54. [PubMed]
49. Den Exter PL, Kooiman J, Huisman MV. Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis. J Thromb Haemost. 2013 May;11(5):998-1000. [PubMed]
50. Ahn S, Lim KS, Lee YS, Lee JL. Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score. Support Care Cancer. 2013 Aug;21(8):2309-13. [PubMed]
51. Khorana AA, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Lee AY. Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial. J Clin Oncol. 2017 Apr 1;35(10):1078-85. [PubMed]
52. Alatri A, Mazzolai L, Font C, Tafur A, Valle R, Marchena PJ, et al.; Riete Investigators T. Low discriminating power of the modified Ottawa VTE risk score in a cohort of patients with cancer from the RIETE registry. Thromb Haemost. 2017 Jul 26;117(8):1630-6. [PubMed]
53. Van Es N, Louzada M, Carrier M, Tagalakis V, Gross PL, Shivakumar S, et al. Predicting the risk of recurrent venous thromboembolism in patients with cancer: a prospective cohort study. Thromb Res. 2018 Mar;163:41-6. [PubMed]
54. Delluc A, Miranda S, Exter PD, Louzada M, Alatri A, Ahn S, et al. Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. Haematologica. 2020 May;105(5):1436-42. [PubMed]
55. Frere C, Crichi B, Wahl C, Lesteven E, Connault J, Durant C, et al. The Ottawa Score Performs Poorly to Identify Cancer Patients at High Risk of Recurrent Venous Thromboembolism: Insights from the TROPIQUE Study and Updated Meta-Analysis. J Clin Med. 2022 Jun 28;11(13):3729. [PubMed]
56. Muñoz AJ, Souto JC, Lecumberri R, Obispo B, Sánchez A, Aparicio J, et al. Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning. Thromb Res. 2023 Aug;228:181-8. [PubMed]
57. Francis CW, Kessler CM, Goldhaber Z, Kovacs MJ, Monreal M, Huisman MV, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost. 2015 Jun;13(6):1028-35. [PubMed]
58. Lecumberri R, Alfonso A, Jiménez D, Fernández Capitán C, Prandoni P, Wells PS, et al. Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. Thromb Haemost. 2013 Oct;110(4):834-43. [PubMed]
59. Sanfilippo K, Luo S, Khorana A, Gage B. Three Available Risk Scores Modestly Predict Hemorrhage in Patients with Cancer-associated Thrombosis (CAT) [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). Disponible en: [PubMed]
60. De Winter MA, Dorresteijn JAN, Ageno W, Ay C, Beyer Westendorf J, Coppens M, et al. Estimating Bleeding Risk in Patients with Cancer-associated Thrombosis: External Validation of Existing Risk Scores and Development of a New Risk Score [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). Disponible en: [PubMed]
61. De Winter MA, Dorresteijn JAN, Ageno W, Ay C, Beyer-Westendorf J, Coppens M, et al. Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score. Thromb Haemost. 2022 May;122(5):818-29. [PubMed]
62. Cohen AT, Wallenhorst C, Choudhuri S, Nassar A, Pollock KG, Martinez C. A Novel Risk Prediction Score for Clinically Significant Bleeding in Patients Anticoagulated for Venous Thromboembolism with Active Cancer. Thromb Haemost. 2024 Apr;124(4):324-36. [PubMed]
63. Muñoz Martín AJ, Palacios ML, Souto JC, Obispo B, Aparicio J, García-Palomo A, et al. Predicting major bleeding events in anticoagulated cancer patients with venous thromboembolism using real-world data and machine learning. J Clin Oncol. 2022;40(16_suppl). Disponible en: [Enlace]
64. Muñoz Martín AJ, Velasco-Durántez V, Sánchez Cánovas M, Fernández Ochoa M, Ortega Morán L, Martínez del Prado P, et al. Validación en el registro TESEO de modelos predictivos de riesgo de sangrado asociado a terapia anticoagulante en pacientes con cáncer y enfermedad tromboembólica venosa desarrollados mediante tecnología de inteligencia artificial. Comunicación oral 24. En: Libro de Comunicaciones SEOM 2022. Congreso SEOM 2022. Madrid, 18-21 octubre 2022.